Equities research analysts expect Supernus Pharmaceuticals (NASDAQ:SUPN) to report earnings of $0.33 per share for the current quarter, Zacks reports. Four analysts have provided estimates for Supernus Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.45 and the lowest estimate coming in at $0.26. Supernus Pharmaceuticals posted earnings per share of $0.19 during the same quarter last year, which would suggest a positive year-over-year growth rate of 73.7%. The company is scheduled to issue its next quarterly earnings report on Tuesday, May 8th.
According to Zacks, analysts expect that Supernus Pharmaceuticals will report full year earnings of $1.85 per share for the current financial year, with EPS estimates ranging from $1.76 to $1.98. For the next year, analysts anticipate that the firm will report earnings of $2.64 per share, with EPS estimates ranging from $2.31 to $3.05. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that cover Supernus Pharmaceuticals.
Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.26 by $0.18. Supernus Pharmaceuticals had a net margin of 18.95% and a return on equity of 28.07%. The business had revenue of $88.44 million for the quarter, compared to analysts’ expectations of $87.84 million.
Supernus Pharmaceuticals stock opened at $45.25 on Friday. Supernus Pharmaceuticals has a 12 month low of $29.95 and a 12 month high of $50.04. The firm has a market cap of $2,373.28, a PE ratio of 35.91 and a beta of 1.11.
In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $48.04, for a total value of $960,800.00. Following the transaction, the vice president now directly owns 32,500 shares of the company’s stock, valued at $1,561,300. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Victor Vaughn sold 60,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 5th. The shares were sold at an average price of $45.33, for a total transaction of $2,719,800.00. Following the completion of the transaction, the vice president now directly owns 24,344 shares in the company, valued at $1,103,513.52. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 100,000 shares of company stock valued at $4,580,200. Company insiders own 6.70% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the business. Elkfork Partners LLC bought a new position in Supernus Pharmaceuticals in the fourth quarter valued at approximately $217,000. Envestnet Asset Management Inc. boosted its stake in Supernus Pharmaceuticals by 2.9% in the fourth quarter. Envestnet Asset Management Inc. now owns 68,599 shares of the specialty pharmaceutical company’s stock valued at $2,734,000 after acquiring an additional 1,964 shares during the last quarter. William Blair Investment Management LLC boosted its stake in Supernus Pharmaceuticals by 32.8% in the fourth quarter. William Blair Investment Management LLC now owns 254,697 shares of the specialty pharmaceutical company’s stock valued at $10,150,000 after acquiring an additional 62,961 shares during the last quarter. MetLife Investment Advisors LLC bought a new position in Supernus Pharmaceuticals in the fourth quarter valued at approximately $856,000. Finally, Iguana Healthcare Management LLC acquired a new stake in Supernus Pharmaceuticals in the fourth quarter worth $1,993,000. 96.30% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Brokerages Anticipate Supernus Pharmaceuticals (SUPN) Will Post Earnings of $0.33 Per Share” was posted by Week Herald and is the sole property of of Week Herald. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://weekherald.com/2018/04/23/brokerages-anticipate-supernus-pharmaceuticals-supn-will-post-earnings-of-0-33-per-share.html.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.